126 related articles for article (PubMed ID: 31258036)
21. Rationale for cannabis-based interventions in the opioid overdose crisis.
Lucas P
Harm Reduct J; 2017 Aug; 14(1):58. PubMed ID: 28821296
[TBL] [Abstract][Full Text] [Related]
22. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: Lessons learned from Seattle, Washington.
Hood JE; Banta-Green CJ; Duchin JS; Breuner J; Dell W; Finegood B; Glick SN; Hamblin M; Holcomb S; Mosse D; Oliphant-Wells T; Shim MM
Subst Abus; 2020; 41(3):356-364. PubMed ID: 31403907
[No Abstract] [Full Text] [Related]
23. Prevention of Opioid Overdose.
Babu KM; Brent J; Juurlink DN
N Engl J Med; 2019 Jun; 380(23):2246-2255. PubMed ID: 31167053
[No Abstract] [Full Text] [Related]
24. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco.
Carter J; Zevin B; Lum PJ
Addict Sci Clin Pract; 2019 May; 14(1):20. PubMed ID: 31060600
[TBL] [Abstract][Full Text] [Related]
25. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort.
Morgan JR; Schackman BR; Weinstein ZM; Walley AY; Linas BP
Drug Alcohol Depend; 2019 Jul; 200():34-39. PubMed ID: 31082666
[TBL] [Abstract][Full Text] [Related]
26. Rapid Adoption of Low-Threshold Buprenorphine Treatment at California Emergency Departments Participating in the CA Bridge Program.
Snyder H; Kalmin MM; Moulin A; Campbell A; Goodman-Meza D; Padwa H; Clayton S; Speener M; Shoptaw S; Herring AA
Ann Emerg Med; 2021 Dec; 78(6):759-772. PubMed ID: 34353655
[TBL] [Abstract][Full Text] [Related]
27. Increasing Access to Buprenorphine in Safety-Net Primary Care Clinics: The New York City Buprenorphine Nurse Care Manager Initiative.
Kaplan-Dobbs M; Kattan JA; Tuazon E; Jimenez C; Saleh S; Kunins HV
Am J Public Health; 2021 Feb; 111(2):215-218. PubMed ID: 33351661
[TBL] [Abstract][Full Text] [Related]
28. Legal Authority for Emergency Medical Services to Increase Access to Buprenorphine Treatment for Opioid Use Disorder.
Davis CS; Carr DH; Glenn MJ; Samuels EA
Ann Emerg Med; 2021 Jul; 78(1):102-108. PubMed ID: 33781607
[TBL] [Abstract][Full Text] [Related]
29. Mobile, Community-Based Buprenorphine Treatment for Veterans Experiencing Homelessness With Opioid Use Disorder: A Pilot, Feasibility Study.
Iheanacho T; Payne K; Tsai J
Am J Addict; 2020 Nov; 29(6):485-491. PubMed ID: 32367557
[TBL] [Abstract][Full Text] [Related]
30. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial.
Liebschutz JM; Crooks D; Herman D; Anderson B; Tsui J; Meshesha LZ; Dossabhoy S; Stein M
JAMA Intern Med; 2014 Aug; 174(8):1369-76. PubMed ID: 25090173
[TBL] [Abstract][Full Text] [Related]
31. A retrospective analysis of treatment and retention outcomes of pregnant and/or parenting women with opioid use disorder.
Lopian KM; Chebolu E; Kulak JA; Kahn LS; Blondell RD
J Subst Abuse Treat; 2019 Feb; 97():1-6. PubMed ID: 30577894
[TBL] [Abstract][Full Text] [Related]
32. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
Sordo L; Barrio G; Bravo MJ; Indave BI; Degenhardt L; Wiessing L; Ferri M; Pastor-Barriuso R
BMJ; 2017 Apr; 357():j1550. PubMed ID: 28446428
[No Abstract] [Full Text] [Related]
33. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
[TBL] [Abstract][Full Text] [Related]
34. Stigma from the Viewpoint of the Patient.
Woods JS; Joseph H
J Addict Dis; 2015; 34(2-3):238-47. PubMed ID: 26076048
[TBL] [Abstract][Full Text] [Related]
35. Integrating buprenorphine treatment into a public healthcare system: the San Francisco Department of Public Health's office-based Buprenorphine Pilot Program.
Hersh D; Little SL; Gleghorn A
J Psychoactive Drugs; 2011; 43(2):136-45. PubMed ID: 21858959
[TBL] [Abstract][Full Text] [Related]
36. A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment.
Fingerhood MI; King VL; Brooner RK; Rastegar DA
Subst Abus; 2014; 35(2):122-6. PubMed ID: 24821346
[TBL] [Abstract][Full Text] [Related]
37. Opioid agonist treatment for pharmaceutical opioid dependent people.
Nielsen S; Larance B; Degenhardt L; Gowing L; Kehler C; Lintzeris N
Cochrane Database Syst Rev; 2016 May; (5):CD011117. PubMed ID: 27157143
[TBL] [Abstract][Full Text] [Related]
38. Best Practices for Pregnant Incarcerated Women With Opioid Use Disorder.
Peeler M; Fiscella K; Terplan M; Sufrin C
J Correct Health Care; 2019 Jan; 25(1):4-14. PubMed ID: 30616487
[TBL] [Abstract][Full Text] [Related]
39. Patterns of non-compliant buprenorphine, levomethadone, and methadone use among opioid dependent persons in treatment.
Casati A; Piontek D; Pfeiffer-Gerschel T
Subst Abuse Treat Prev Policy; 2014 May; 9():19. PubMed ID: 24885218
[TBL] [Abstract][Full Text] [Related]
40. A comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: A view from the payer perspective.
Kinsky S; Houck PR; Mayes K; Loveland D; Daley D; Schuster JM
J Subst Abuse Treat; 2019 Sep; 104():15-21. PubMed ID: 31370980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
